LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Sepsis Host-Response PCR Test Enables Early Targeted Therapies

By LabMedica International staff writers
Posted on 29 Mar 2023

Sepsis is a leading cause of hospital deaths, resulting in significant human and economic costs. The lack of effective antimicrobials to treat sepsis leads to the death of 11 million people annually. Delayed diagnosis of sepsis can increase the risk of developing septic shock by 4-9% per hour. Early identification of sepsis in patients with ambiguous symptoms can help healthcare professionals provide timely targeted treatment, even before the results of confirmatory tests such as microbiology cultures are available. Now, a host (patient) immune response test can identify 19 mRNA biomarkers of infection, sepsis and septic shock, and can also be used to monitor patient response to treatment.

AcuSept from Acumen Diagnostics Pte. Ltd. (Singapore) is a sepsis host-response blood test based on specific biomarkers that evaluates the host's immune response dysregulation during systemic infection and sepsis by analyzing the gene expression signature of 19 leukocyte mRNA biomarkers, using RT-PCR. The sepsis PCR-based diagnostic test generates results within five hours of patient sample collection.


Image: The AcuSept PCR Test is a sepsis host-response blood test based on specific biomarkers (Photo courtesy of Pexels)
Image: The AcuSept PCR Test is a sepsis host-response blood test based on specific biomarkers (Photo courtesy of Pexels)

AcuSept results provide valuable information about infection and sepsis risk and progression. The test can diagnose culture-negative sepsis, which can be difficult to detect using traditional microbiology culture tests that are slower and less sensitive. By overcoming these limitations, AcuSept enables patient triage and monitoring and can be used as a complementary tool to clinical assessments and other diagnostic parameters. AcuSept can inform the selection of appropriate treatment bundles based on the severity risk of sepsis, from early sepsis to severe sepsis and septic shock, and allows for the monitoring of patient response to treatment.

Acumen's clinical studies have demonstrated that AcuSept outperforms other single-biomarker tests in detecting sepsis, and is highly effective in diagnosing culture-negative sepsis. The test's superior positive and negative predictive values enable it to detect infection in patients, providing supplementary information to pathogen identification tests. With AcuSept test results, doctors can gain crucial insights into a patient's condition, allowing for more comprehensive assessments and targeted treatment decisions with greater speed.

Related Links:
Acumen Diagnostics 


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit

Latest Microbiology News

New Test Diagnoses Bacterial Meningitis Quickly and Accurately
29 Mar 2023  |   Microbiology

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
29 Mar 2023  |   Microbiology

New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
29 Mar 2023  |   Microbiology